indomethacin has been researched along with Weight Loss in 10 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred eight cancer patients who experienced progressive cachexia due to solid, mainly gastrointestinal tumors were randomized to receive twice daily a cyclo-oxygenase inhibitor (controls; indomethacin, 50 mg twice a day) or indomethacin and erythropoietin, provided on individual basis to prevent development of progressive anemia (study patients; indomethacin, 50 mg twice a day plus rhEPO; range, 12,000-30,000 units per week)." | 5.08 | Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. ( Bosaeus, I; Brevinge, H; Daneryd, P; Körner, U; Lindholm, E; Lundholm, K; Pettersson, C; Sandström, R; Svanberg, E, 1998) |
| "Indomethacin administration caused weight loss, increased the signs of severe infection and worsened histopathological damage, leading to 100% mortality during CDI." | 3.88 | Indomethacin increases severity of Clostridium difficile infection in mouse model. ( Aronoff, DM; Bergin, IL; Castro-Córdova, P; Gil, F; Kirk, LA; Muñoz-Miralles, J; Paredes-Sabja, D; Trindade, BC, 2018) |
| "To assess the putative involvement of NF-kappaB and pro-inflammatory cytokines in the pathogenesis of cancer cachexia and the therapeutic efficacy of indomethacin (IND) on cachexia." | 3.72 | Role of NF-kappaB and cytokine in experimental cancer cachexia. ( Jiang, J; Jiang, ZW; Li, JS; Li, N; Tian, J; Zhou, W, 2003) |
| "Propranolol treatment was associated with a significant reduction in plasma concentrations of free fatty acids (FFA), but not in plasma glycerol." | 2.67 | Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours. ( Hyltander, A; Körner, U; Lundholm, KG, 1993) |
| "Pain and cachexia are two of the most debilitating aspects of rheumatoid arthritis." | 1.33 | Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. ( Ho, WH; Pons, J; Rosenthal, A; Shelton, DL; Zeller, J, 2005) |
| "Weight-losing untreated cancer patients had elevated resting energy expenditure compared to undernourished non-cancer patients (23." | 1.32 | Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. ( Bosaeus, I; Daneryd, P; Hyltander, A; Körner, U; Lundholm, K, 2004) |
| "Symptomatic patent ductus arteriosus (sPDA) may occur in up to 50% of very-low-birth-weight (VLBW, less than or equal to 1500 g) infants." | 1.28 | Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. ( Mouzinho, AI; Risser, R; Rosenfeld, CR, 1991) |
| "The ability of 13 of the cancer samples to induce muscle proteolysis was significantly inhibited by incubation of muscles in presence of indomethacin (10 microM)." | 1.28 | Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. ( Belizario, JE; Chenker, E; Katz, M; Raw, I, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muñoz-Miralles, J | 1 |
| Trindade, BC | 1 |
| Castro-Córdova, P | 1 |
| Bergin, IL | 1 |
| Kirk, LA | 1 |
| Gil, F | 1 |
| Aronoff, DM | 1 |
| Paredes-Sabja, D | 1 |
| Zhou, W | 1 |
| Jiang, ZW | 1 |
| Tian, J | 1 |
| Jiang, J | 1 |
| Li, N | 1 |
| Li, JS | 1 |
| Lundholm, K | 2 |
| Daneryd, P | 2 |
| Körner, U | 3 |
| Hyltander, A | 2 |
| Bosaeus, I | 2 |
| Shelton, DL | 1 |
| Zeller, J | 1 |
| Ho, WH | 1 |
| Pons, J | 1 |
| Rosenthal, A | 1 |
| Molloy, RG | 1 |
| Holzheimer, R | 1 |
| Nestor, M | 1 |
| Collins, K | 1 |
| Mannick, JA | 1 |
| Rodrick, ML | 1 |
| Lundholm, KG | 1 |
| Svanberg, E | 1 |
| Lindholm, E | 1 |
| Sandström, R | 1 |
| Brevinge, H | 1 |
| Pettersson, C | 1 |
| Mouzinho, AI | 1 |
| Rosenfeld, CR | 1 |
| Risser, R | 1 |
| Belizario, JE | 1 |
| Katz, M | 1 |
| Chenker, E | 1 |
| Raw, I | 1 |
| Mahony, SM | 1 |
| Tisdale, MJ | 1 |
2 trials available for indomethacin and Weight Loss
| Article | Year |
|---|---|
Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours.
Topics: Basal Metabolism; Energy Metabolism; Female; Hormones; Humans; Indomethacin; Male; Morphine; Neoplas | 1993 |
Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.
Topics: Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Cachexia; Cyclooxygenase Inhibitors; Energy M | 1998 |
8 other studies available for indomethacin and Weight Loss
| Article | Year |
|---|---|
Indomethacin increases severity of Clostridium difficile infection in mouse model.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Clostridioides difficile; C | 2018 |
Role of NF-kappaB and cytokine in experimental cancer cachexia.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Composition; Cachexia; Coloni | 2003 |
Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Sedim | 2004 |
Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, Experimental; C | 2005 |
Granulocyte-macrophage colony-stimulating factor modulates immune function and improves survival after experimental thermal injury.
Topics: Animals; Burns; Cell Division; Dose-Response Relationship, Drug; Drug Therapy, Combination; Granuloc | 1995 |
Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989.
Topics: Analysis of Variance; Cardiac Surgical Procedures; Colloids; Ductus Arteriosus, Patent; Female; Flui | 1991 |
Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Blood Proteins; Cachexia; Child; Diaphragm; Fem | 1991 |
Role of prostaglandins in tumour necrosis factor induced weight loss.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Dinoprostone; Female; Indomethacin; Mice; Recombinant Prote | 1989 |